Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Proceedings of the European Charcot Foundation Symposium A Reappraisal of Nutrition and Environment in Multiple Sclerosis, European Charcot Foundation Symposium, December 2-4, 2010, Fiuggi, Italy.
Compressive syndrome of internal jugular veins in multiple sclerosis: does it matter?
Modulation of the Innate Immune Response by Human Neural Precursors Prevails Over Oligodendrocyte Progenitor Remyelination to Rescue a Severe Model Of Pelizaeus-Merzbacher Disease.
Neuroprotection in Huntington's disease: a 2-year study on minocycline.
Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein.
Comorbid Multiple Sclerosis and TDP-43 Proteinopathy in a Gulf War Sea Captain.
The thalamus and multiple sclerosis: Modern views on pathologic, imaging, and clinical aspects.
Decreased urinary level of melatonin as a marker of disease severity in patients with multiple sclerosis.
Sustained-Release Fampridine (4-Aminopyridine) in Multiple Sclerosis: Efficacy and Impact on Motor Function.
Multiple sclerosis: Five new things.
The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Integrin/Chemokine Receptor Interactions in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.
Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients.
Neuroprotection With Riluzole Patients With Early Multiple Sclerosis
Decrease in newly generated oligodendrocytes leads to motor dysfunctions and changed myelin structures that can be rescued by transplanted cells.
Purinergic trophic signalling in glial cells: functional effects and modulation of cell proliferation, differentiation, and death.
The gut microbiota and its correlations with the central nervous system disorders.
Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review.
Ibuprofen-induced unilateral optic neuritis.
Role of Platelets in Neurodegenerative Diseases: A Universal Pathophysiology.
Secukinumab: first global approval.
Association between a Genetic Variant of Type-1 Cannabinoid Receptor and Inflammatory Neurodegeneration in Multiple Sclerosis.
[Cost of multiple sclerosis in France.]
Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension.
Low dose naltrexone for induction of remission in Crohn's disease.
Pages
« first
‹ previous
…
214
215
216
217
218
219
220
221
222
…
next ›
last »